The health care company Johnson & Johnson said Tuesday that its second-quarter revenue was flat, primarily because of recalls of nonprescription medicines. But the company still reported a 7.5 percent increase in net income.

In a rare move, Johnson & Johnson reduced its 2010 profit forecast by 15 cents a share. The company cited the recalls of tens of millions of bottles of Tylenol and other well-known brands, long-term closure of the suburban Philadelphia factory that made them and unfavorable currency exchange rates.

Net income was $3.45 billion, or $1.23 a share, up from $3.21 billion, or $1.15 a share, a year earlier. But the improvement was almost entirely the result of a lower tax bill for the quarter.

Excluding a one-time gain of $67 million from settling litigation, earnings would have been $3.38 billion, or $1.21 a share. On that basis, the earnings matched the forecast of analysts polled by Thomson Reuters. But the analysts had expected revenue of $15.66 billion, $300 million more than the company reported.